CS
ARRY

Candriam SCA’s Array Biopharma Inc ARRY Stock Holding History

Candriam SCA’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-992,510
Closed -$45.8M – 850
2019
Q2 		$45.8M Sell
992,510
-612,970
-38% -$17.2M 0.57% 28
2019
Q1 		$39.1M Sell
1,605,480
-73,230
-4% -$1.52M 0.5% 42
2018
Q4 		$23.9M Buy
1,678,710
+327,522
+24% +$4.97M 0.37% 52
2018
Q3 		$20.5M Buy
1,351,188
+601,300
+80% +$9.21M 0.27% 79
2018
Q2 		$12.6M Buy
749,888
+174,888
+30% +$2.78M 0.2% 131
2018
Q1 		$9.38M Buy
575,000
+35,000
+6% +$561K 0.16% 169
2017
Q4 		$6.91M Sell
540,000
-204,000
-27% -$2.32M 0.12% 211
2017
Q3 		$9.15M Buy
744,000
+279,000
+60% +$2.59M 0.16% 167
2017
Q2 		$3.89M Buy
465,000
+10,000
+2% +$81.8K 0.07% 321
2017
Q1 		$4.07M Sell
455,000
-300,000
-40% -$3.19M 0.08% 292
2016
Q4 		$6.64M Sell
755,000
-55,000
-7% -$405K 0.15% 167
2016
Q3 		$5.47M Sell
810,000
-39,000
-5% -$151K 0.13% 179
2016
Q2 		$3.02M Buy
849,000
+190,000
+29% +$619K 0.08% 249
2016
Q1 		$1.93M Buy
+659,000
New +$1.97M 0.05% 327

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Candriam SCA's ARRY Position: Q3 2019 in Review

Candriam SCA sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 992,510 shares — an estimated $45.8M sold.

Candriam SCA first reported a position in ARRY in Q1 2016 and held it in 14 quarters. The position peaked at $45.8M in Q2 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Candriam SCA reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Candriam SCA sold 992,510 Array Biopharma Inc shares in Q3 2019, an estimated $45.8M.
  • Candriam SCA first reported a position in Array Biopharma Inc in Q1 2016 and held it in 14 quarters.
  • Candriam SCA's Array Biopharma Inc position peaked at $45.8M in Q2 2019.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Candriam SCA's 13F filing for Q3 2019, filed 21 Oct 2019.